Cargando…

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

BACKGROUND: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer. METHODS: Hydralazine was administered to cohorts of 4 patients at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zambrano, Pilar, Segura-Pacheco, Blanca, Perez-Cardenas, Enrique, Cetina, Lucely, Revilla-Vazquez, Alma, Taja-Chayeb, Lucía, Chavez-Blanco, Alma, Angeles, Enrique, Cabrera, Gustavo, Sandoval, Karina, Trejo-Becerril, Catalina, Chanona-Vilchis, Jose, Duenas-González, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131894/ https://www.ncbi.nlm.nih.gov/pubmed/15862127 http://dx.doi.org/10.1186/1471-2407-5-44

Ejemplares similares

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2006)

Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma
por: Candelaria, Myrna, et al.
Publicado: (2006)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

New molecular targets against cervical cancer
por: Duenas-Gonzalez, Alfonso, et al.
Publicado: (2014)

Up-regulation of HLA class I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2007)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer
por: Lopez-Graniel, Carlos, et al.
Publicado: (2005)

Hydralazine-Induced Vasculitis
por: Gandhi, Pulkit, et al.
Publicado: (2023)

Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model
por: Medina, Luis-Alberto, et al.
Publicado: (2008)

Epigenetics of cervical cancer. An overview and therapeutic perspectives
por: Dueñas-González, Alfonso, et al.
Publicado: (2005)

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
por: Zuckerman, Roman, et al.
Publicado: (2018)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Hydralazine-Induced Vasculitis With Gastrointestinal Pseudomelanosis
por: Novikov, Aleksey, et al.
Publicado: (2014)

Clinical Characteristics of Hydralazine-induced Lupus
por: Timlin, Homa, et al.
Publicado: (2019)

Hydralazine-Induced Isolated Lupus Nephritis
por: Khan, Naseer, et al.
Publicado: (2020)

Hydralazine-Associated Vasculitis and Pulmonary Hemorrhage
por: Strubchevska, Kateryna, et al.
Publicado: (2023)

Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients
por: Cetina, Lucely, et al.
Publicado: (2009)

Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
por: Bibby, M. C., et al.
Publicado: (1992)

Anti-neoplastic properties of hydralazine in prostate cancer
por: Graça, Inês, et al.
Publicado: (2014)

ANA-Negative Hydralazine-Induced Pericardial Effusion
por: Zeitjian, Vicken, et al.
Publicado: (2017)

Hydralazine-induced vasculitis presenting with ocular manifestations
por: Hawn, Vivian S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_914b5c4dd2vof56q1q77be9iba